OC-07 - Decoding risk for thromboembolic events in lymphoma patients

Risk of thromboembolism with lymphoma: myth or reality?

“…However, recent studies, including Borg et al in this issue of Leukaemia and Lymphoma, have demonstrated that the risk of TE in patients with non-Hodgkins lymphoma (NHL) is clinically relevant and that in appropriately risk-stratified populations, the observed risk is potentially comparable to other high TE risk subgroups. [4][5][6][7][8][9][10][11][12] In retrospective studies and pooled analyses the reported incidence of TE among patients with NHL varies substantially from 1-15%. This variability in reported risk is largely due to the heterogeneity in patient-and tumour-related factors (as well as therapy administered), with high grade lymphoma, such as diffuse large B-cell -including primary CNS and mediastinal lymphoma -conferring the highest rates.…”

“…Importantly, in all reported studies, the majority (>90%) of TE events among patients with NHL occur early, generally within 3 months from diagnosis, and during therapy. [4,8,9,12,13] The risk appears greatest in those patients with higher grade disease (i.e. DLBCL vs low grade lymphoma), primary CNS lymphoma, prior TE, more advanced stage disease, extranodal sites, increased BMI (>30kg/m 2 ) and reduced performance status (ECOG 2-4).…”